Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial.

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWonshik HanEKEunhye KangHKHong Kyu Kim

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Han et al. (2024) studied this question.

synapsesocial.com/papers/68e66c5ab6db6435875f771ehttps://doi.org/10.1200/jco.2024.42.16_suppl.595
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PO1-14-12: Quantitative Biomarkers and 21-Gene Assay Results Predict Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer2024
  2. 2Abstract PO4-17-06: Real World Data: A single institute experience with neoadjuvant endocrine therapy for ER+ breast cancer — clinical response rates, clinical predictors of response and long-term outcomes following breast conserving surgery2024
  3. 3Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis.2024
  4. 4Beyond Chemotherapy: Network Meta‐Analysis Reveals Optimal Neoadjuvant Strategies for Luminal Breast Cancer2026 · 2 citations
  5. 5A response-adapted and genomically informed strategy to optimize neoadjuvant chemotherapy versus endocrine therapy plus CDK4/6 inhibition in high-risk HR+/HER2− breast cancer.2026